After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.

The promising drug combination was discovered and tested by Karuna Therapeutics, which Bristol Myers Squibb acquired in March. Bristol Myers Squibb will sell the drug combination under the brand name ...

Kasey Palmer has opened up on his Coventry City departure, claiming he was offered a new contract which was then withdrawn, forcing him to make the switch to Championship rivals Hull. The 27-year ...

West Midlands Police, ambulance fire service staff were sent to the scene but unable to save the man A Coventry man has died after falling from the balcony of a tower block. Police were called to ...

Swansea earned their first points on the road this season by securing a 2-1 victory over Coventry at the CBS Arena. Luke Williams' side raced into a two-goal lead in the opening half-hour thanks ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.

A bus gate in Coventry, which issued 25,000 fines in half a year, has been made permanent. Drivers face a £70 fine for breaching the restriction at Hales Street, which Coventry City Council ...

But Coventry's ring road, a well-used city landmark, passed its 50th anniversary this week. Its notoriety stems from the way drivers have to get on and off the raised concrete roadway at 40mph ...

Developed by Karuna Therapeutics, now part of Bristol Myers Squibb (BMS), it works by targeting receptors in the brain that modulate dopamine release, rather than blocking it directly. Results of ...

Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a shareholder lawsuit that ...